单片药丸组合与安洛迪平的瓦尔萨坦的药理动力学和安全性高度变化与其通用配方:一个随机的,三循环,三序,部分复制的交叉第一阶段生物等效性临床试验
Bo Qiu1, Haojing Song1, Congyang Ding1
1Phase I Clinical Trial Laboratory, Hebei General Hospital, Shijiazhuang, China.
这项研究表明,瓦尔萨坦/阿姆洛迪平单片组合在禁食和食条件下具有生物等价性. 试验和参考配方在中国试验者中显示出类似的安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药物开发 药物开发
背景情况:
- 高血压管理通常涉及组合疗法.
- 单片药组合 (SPC) 改善了患者的药物遵守.
- 瓦尔沙坦/阿姆洛迪平SPC结合了一种血管激素II受体阻断剂 (ARB) 和一种通道阻断剂 (CCB).
研究的目的:
- 为了证明与参考配方相比,测试瓦尔萨坦/阿姆洛迪平SPC的生物等价性.
- 在禁食和食后条件下评估生物等价性.
- 在健康的中国受试者中评估配方的安全性.
主要方法:
- 进行了一项随机的,三序复制的交叉试验.
- 药理动力学 (PK) 参数使用平均生物等效 (ABE) 和参考尺度平均生物等效 (RSABE) 方法进行分析.
- 招募了45名符合条件的参与者,在禁食和食后状态下进行了分析.
主要成果:
- 对于瓦尔沙坦,Cmax的RSABE和AUC的ABE满足了生物等价性标准.
- 对于阿姆洛迪平,Cmax和AUC的ABE证明了生物等价性 (90%CI80%-125%).
- 这两种配方均表现出相似的安全性.
结论:
- 测试瓦尔萨坦/阿姆洛迪平SPC与参考配方生物等价.
- 该SPC适用于健康的中国受试者在禁食和食后条件下使用.
- 这些发现支持使用此SPC治疗高血压.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
相关概念视频
Bioequivalence: Overview
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Time Course of Drug Effect
Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
Dose-Response Relationship: Potency and Efficacy
Bioavailability: Overview
